CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy

<div><b>Locoregional recurrence-free survival</b>. Figure <a href="../fig3/">3</a> illustrates locoregional recurrence-free survival curves for patients with CDK9 positive versus CDK9 negative tumors. There is no statistically significant or observable difference in the two survival curves.</div>

International Journal of Breast Cancer

fig3

Figure 3

Figure 3: CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy 

Figure 3 | CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy 